Abstract：
Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are stubborn inflammatory skin diseases categorized as neutrophilic hypodermal dermatoses. These conditions exhibit connections with other autoinflammatory disorders driven by immune responses. Their pathogenesis is complex, rooted in significant imbalances in both innate and adaptive immune systems, particularly featuring elevated levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1, IL-8, IL-17, and IL-23. Studies involving skin tissue pathology and serology have indicated that targeting specific cytokines can bring therapeutic benefits. Indeed, many patients in clinical settings have responded positively to such interventions. Yet, given the diverse cytokines in play, focusing on a single one with antibody therapy might not always be effective. When resistance to biologics emerges, a combined approach targeting multiple overactive cytokines with immunosuppressants, for example cyclosporine and Janus kinase inhibitors, could be an option. In the current review, we explore recent therapeutic developments for PG and HS.
摘要：
坏疽性脓皮病（PG）和化脓性汗腺炎（HS）是顽固的炎症性皮肤病，被归类为中性粒细胞皮下皮肤病。这些病症表现出与由免疫应答驱动的其他自身炎性疾病的联系。其发病机制复杂,根植于先天和适应性免疫系统的显著失衡，特别是肿瘤坏死因子-α（TNF-α）水平升高，白细胞介素(IL)-1、IL-8、IL-17和IL-23。涉及皮肤组织病理学和血清学的研究已经表明靶向特定细胞因子可以带来治疗益处。的确,许多临床患者对此类干预措施反应积极.然而，考虑到不同的细胞因子在起作用，专注于单一的抗体治疗可能并不总是有效的。当出现对生物制剂的抵抗时，一种针对多种过度活跃的细胞因子与免疫抑制剂的联合方法，例如环孢菌素和Janus激酶抑制剂，可能是一个选择。在当前的审查中，我们探讨了PG和HS的最新治疗进展。
